Topoisomerase-I inhibitors in gynecologic tumors (Q33541928)

27 July 2017

1 reference

title

Topoisomerase-I inhibitors in gynecologic tumors (English)

1 reference

27 July 2017

Haluska P

1 reference

27 July 2017

Rubin E

series ordinal

1 reference

27 July 2017

Verschraegen CF

series ordinal

1 reference

27 July 2017

publication date

1 February 1999

1 reference

Hematology / Oncology Clinics of North America

27 July 2017

published in

1 reference

27 July 2017

1 reference

27 July 2017

1 reference

27 July 2017

page(s)

43-61, vii-viii

1 reference

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Identification of a nucleolin binding site in human topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Preferential binding of the carboxylate form of camptothecin by human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Characterization of camptothecin-resistant chinese hamster lung cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

The anatomy of A-, B-, and Z-DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

DNA structure from A to Z.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

The DNA Helix and How it is Read

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

The yeast type I topoisomerase Top3 interacts with Sgs1, a DNA helicase homolog: a potential eukaryotic reverse gyrase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Nucleolin functions in the first step of ribosomal RNA processing.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Interaction between the N-terminus of human topoisomerase I and SV40 large T antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Human TOP3: a single-copy gene encoding DNA topoisomerase III

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Interaction between the N-terminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Supercoiling of the DNA template during transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

DNA topoisomerase poisons as antitumor drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

p53 status and the efficacy of cancer therapy in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Inhibition of cis‐diamminedichloroplatinum (II)‐induced DNA interstrand cross‐link removal by 7‐ethyl‐10‐hydroxy‐camptothecin in HST‐1 human squamous‐carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Targeted disruption of the mouse topoisomerase I gene by camptothecin selection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Simian virus 40 large T antigen binds to topoisomerase I.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

1 reference

7 January 2021

Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Failure to unwind causes cancer. Genome stability

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Sgs1: a eukaryotic homolog of E. coli RecQ that interacts with topoisomerase II in vivo and is required for faithful chromosome segregation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

Processing of topoisomerase I cleavable complexes into DNA damage by transcription.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970153-2

7 January 2021

10.1016/S0889-8588(05)70153-2

Identifiers

DOI

1 reference

27 July 2017

1 reference